The Frederick National Laboratory for Cancer Research (FNLCR) is developing the Advanced Technology Research Facility
(ATRF), a new, 340,000 square foot translational R&D facility, consisting of advanced technology laboratories,
biopharmaceutical development, and cGMP biopharmaceutical production facilities. The facility is designed to foster
co-located partnership projects, with dedicated laboratory and “think tank” space for collaborative work with
partners across a continuum of translational R&D technologies and platforms, including genomics, proteomics, nanotechnology,
molecular diagnostics, bioinformatics, and biopharmaceutical development, and more.
The ATRF will help bring together partners from the government, industry, academia, and the nonprofit sector to
accelerate the translation of basic research findings into clinical technologies, diagnostics, and treatments
for patients with cancer and AIDS. About one-third of the ATRF is available for partnership projects where the
partner can co-locate resources thereby facilitating business and technology objectives of both the partners and
View available partnership space.
The Advanced Technology Program and the Biopharmaceutical Development Program are located in the new facility.
The ATRF is the anchor facility of the National Cancer
Institute at Riverside Research Park (RRP). RRP is a premier
biomedical research campus in Frederick, MD, which is growing through location of companies and organizations
with complementary and synergistic technologies, products, services, and capabilities that are important to creating
the next generation of therapies for cancer and AIDS.
For more information about strategic co-location opportunities, please contact:
Bruce Crise Ph.D.
Director Business Development
Partnership Development Office
Frederick National Laboratory for Cancer Research
Typed the characters seen in the image below to continue.
Sending Mail ...
The Frederick National Lab is a Federally Funded Research and Development Center operated by SAIC-Frederick for the National Cancer Institute.